TBPH
Income statement / Annual
Last year (2023), Theravance Biopharma, Inc.'s total revenue was $57.42 M,
an increase of 11.84% from the previous year.
In 2023, Theravance Biopharma, Inc.'s net income was -$55.19 M.
See Theravance Biopharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$57.42 M
|
$51.35 M
|
$55.31 M
|
$71.86 M
|
$73.41 M
|
$60.37 M
|
$15.39 M
|
$48.65 M
|
$42.13 M
|
$11.69 M
|
Cost of Revenue |
$6.05 M |
$6.59 M |
$7.29 M |
$260.95 M |
$219.25 M |
$715,000.00 |
$6.03 M |
$2.89 M |
$4.66 M |
$4.06 M |
Gross Profit |
$51.37 M |
$44.76 M |
$48.03 M |
-$189.10 M |
-$145.83 M |
$59.66 M |
$9.36 M |
$45.75 M |
$37.47 M |
$7.63 M |
Gross Profit Ratio |
0.89 |
0.87 |
0.87 |
-2.63 |
-1.99 |
0.99 |
0.61 |
0.94 |
0.89 |
0.65 |
Research and Development
Expenses |
$40.62 M
|
$63.39 M
|
$193.66 M
|
$260.95 M
|
$219.25 M
|
$201.35 M
|
$173.89 M
|
$141.71 M
|
$129.17 M
|
$168.52 M
|
General & Administrative
Expenses |
$65.00 M
|
$59.07 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling & Marketing
Expenses |
$5.10 M
|
$8.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$70.10 M
|
$67.07 M
|
$99.30 M
|
$108.66 M
|
$106.08 M
|
$97.06 M
|
$95.59 M
|
$84.51 M
|
$90.20 M
|
$71.65 M
|
Other Expenses |
$0.00 |
$0.00 |
$0.00 |
-$1.61 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Operating Expenses |
$110.72 M |
$130.47 M |
$292.95 M |
$369.61 M |
$325.33 M |
$298.41 M |
$269.48 M |
$226.22 M |
$219.37 M |
$240.17 M |
Cost And Expenses |
$110.72 M |
$130.47 M |
$292.95 M |
$369.61 M |
$325.33 M |
$299.12 M |
$275.51 M |
$229.12 M |
$224.03 M |
$244.23 M |
Interest Income |
$9.12 M |
$8.55 M |
$1.11 M |
$2.83 M |
$8.40 M |
$11.97 M |
$4.96 M |
$1.31 M |
$631,000.00 |
$1.87 M |
Interest Expense |
$2.35 M |
$6.37 M |
$46.89 M |
$44.59 M |
$31.86 M |
$10.48 M |
$8.55 M |
$1.40 M |
$0.00 |
$0.00 |
Depreciation &
Amortization |
$6.05 M
|
$6.59 M
|
$7.29 M
|
$6.64 M
|
$6.52 M
|
$3.17 M
|
$4.03 M
|
$3.12 M
|
$2.99 M
|
$2.66 M
|
EBITDA |
-$40.28 M
|
-$70.57 M
|
-$132.55 M
|
-$226.49 M
|
-$209.82 M
|
-$215.60 M
|
-$255.16 M
|
-$179.16 M
|
-$178.91 M
|
-$232.54 M
|
EBITDA Ratio |
-0.7 |
-1.37 |
-2.4 |
-3.15 |
-2.86 |
-3.57 |
-16.58 |
-3.68 |
-4.25 |
-19.9 |
Operating Income Ratio
|
-0.93
|
-1.79
|
-4.66
|
-4.14
|
-3.43
|
-3.95
|
-16.91
|
-3.71
|
-4.32
|
-19.9
|
Total Other
Income/Expenses Net |
$4.02 M
|
-$858,000.00
|
$58.21 M
|
$11.22 M
|
$10.24 M
|
$11.18 M
|
-$8.00 M
|
-$92,000.00
|
$631,000.00
|
$1.87 M
|
Income Before Tax |
-$49.27 M |
-$92.82 M |
-$199.58 M |
-$286.54 M |
-$241.68 M |
-$226.09 M |
-$271.71 M |
-$180.56 M |
-$181.27 M |
-$230.67 M |
Income Before Tax Ratio
|
-0.86
|
-1.81
|
-3.61
|
-3.99
|
-3.29
|
-3.74
|
-17.66
|
-3.71
|
-4.3
|
-19.74
|
Income Tax Expense |
$5.92 M |
$9,000.00 |
-$151,000.00 |
-$8.52 M |
-$5.22 M |
-$10.56 M |
$13.69 M |
$10.11 M |
$951,000.00 |
$6.36 M |
Net Income |
-$55.19 M |
-$92.82 M |
-$199.43 M |
-$278.02 M |
-$236.46 M |
-$215.52 M |
-$285.41 M |
-$190.67 M |
-$182.22 M |
-$237.04 M |
Net Income Ratio |
-0.96 |
-1.81 |
-3.61 |
-3.87 |
-3.22 |
-3.57 |
-18.55 |
-3.92 |
-4.33 |
-20.28 |
EPS |
-1 |
-1.26 |
-2.87 |
-4.46 |
-4.25 |
-3.99 |
-5.45 |
-4.26 |
-5.34 |
-7.46 |
EPS Diluted |
-1 |
-1.26 |
-2.87 |
-4.46 |
-4.25 |
-3.99 |
-5.45 |
-4.26 |
-5.34 |
-7.46 |
Weighted Average Shares
Out |
$55.30 M
|
$73.59 M
|
$69.46 M
|
$62.35 M
|
$55.61 M
|
$53.97 M
|
$52.35 M
|
$44.71 M
|
$34.15 M
|
$31.76 M
|
Weighted Average Shares
Out Diluted |
$55.30 M
|
$73.59 M
|
$69.46 M
|
$62.35 M
|
$55.61 M
|
$53.97 M
|
$52.35 M
|
$44.71 M
|
$34.15 M
|
$31.76 M
|
Link |
|
|
|
|
|
|
|
|
|
|